RT Journal Article
T1 Downregulation of clusterin mediates sensitivity to protein kinase inhibitors in breast cancer cells.
A1 Redondo-Bautista, Maximino
A1 García Aranda, Marilina
A1 Roldán Cardenete, María José
A1 Callejón, Gonzalo
A1 Serrano-Garballo, Alfonso
A1 Jimenez, Eugenio
A1 Téllez-Santana, Teresa
K1 Glucoproteínas
K1 Enzimas - Inhibidores
K1 Oligonucleótidos
AB The efficacy of protein kinase inhibitors (PKIs) has been shown in clinical assays for cancer, but as isolated agents, they only have a modest effect. One of the most important characteristics of mitogen-activated PKIs is their ability to decrease the apoptotic threshold of cancer cells, sensitizing them to the action of other antiapoptotic agents. The secretory clusterin protein is an inhibitor of apoptosis with a cytoprotective function. We describe the use of clusterin-specific antisense oligonucleotides and siRNA to sensitize breast carcinoma cells to several PKIs. MCF-7 and MDA-MB-231 cells were treated with antisense oligonucleotide or siRNA to clusterin and the following PKIs: H-89, chelerythrine and genistein. The three inhibitors used in this study upregulated clusterin expression and treatments that included antisense oligonucleotide or siRNA to clusterin reduced the number of viable cells more effectively than did treatment with the drugs alone. Therefore, treatment with such combinations may benefit patients with breast cancer.
PB Lipincott
YR 2015
FD 2015
LK https://hdl.handle.net/10630/36807
UL https://hdl.handle.net/10630/36807
LA eng
NO Redondo M, García-Aranda M, Roldan MJ, Callejón G, Serrano A, Jiménez E, Téllez T. Downregulation of clusterin mediates sensitivity to protein kinase inhibitors in breast cancer cells. Anticancer Drugs. 2015 Jan;26(1):85-9. doi: 10.1097/CAD.0000000000000164. PMID: 25144344.
NO https://openpolicyfinder.jisc.ac.uk/id/publication/8720
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026